News

GH Research PLC: GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalen ...
Royalty Pharma plc: Royalty Pharma Reports First Quarter 2025 Results
Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...